Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
46
SLNO Quote, Financials, Valuation and Earnings
Last price:
$37.22
Seasonality move
:
19.84%
Day range:
$36.89 - $39.79
52-week range:
$36.89 - $90.32
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
18.45x
P/B ratio:
4.04x
Volume:
1.7M
Avg. volume:
1.7M
1-year change:
-27.45%
Market cap:
$2B
Revenue:
--
EPS (TTM):
-$1.84
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SLNO
Soleno Therapeutics, Inc.
|
$88.5M | $0.08 | -- | -- | $111.92 |
|
ASRT
Assertio Holdings, Inc.
|
$6.2M | -$1.80 | -80.74% | -9.4% | $39.94 |
|
MRKR
Marker Therapeutics, Inc.
|
$682K | -$0.19 | -69.71% | -54.94% | $7.87 |
|
NKTR
Nektar Therapeutics
|
$10.4M | -$3.29 | -3.45% | -1474.64% | $123.43 |
|
RCEL
AVITA Medical, Inc.
|
$17.4M | -$0.38 | -0.82% | -63.86% | $8.51 |
|
RIGL
Rigel Pharmaceuticals, Inc.
|
$68.7M | $1.20 | 14.34% | 26.98% | $51.60 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SLNO
Soleno Therapeutics, Inc.
|
$37.24 | $111.92 | $2B | -- | $0.00 | 0% | 18.45x |
|
ASRT
Assertio Holdings, Inc.
|
$12.38 | $39.94 | $79.4M | -- | $0.00 | 0% | 4.61x |
|
MRKR
Marker Therapeutics, Inc.
|
$1.43 | $7.87 | $23.8M | -- | $0.00 | 0% | 3.88x |
|
NKTR
Nektar Therapeutics
|
$71.33 | $123.43 | $1.2B | -- | $0.00 | 0% | 73.55x |
|
RCEL
AVITA Medical, Inc.
|
$4.16 | $8.51 | $126.9M | -- | $0.00 | 0% | 1.62x |
|
RIGL
Rigel Pharmaceuticals, Inc.
|
$34.32 | $51.60 | $623M | 5.57x | $0.00 | 0% | 2.23x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SLNO
Soleno Therapeutics, Inc.
|
9.62% | -2.386 | 1.45% | 15.77x |
|
ASRT
Assertio Holdings, Inc.
|
29.83% | 1.399 | 53.04% | 1.43x |
|
MRKR
Marker Therapeutics, Inc.
|
-- | 2.330 | -- | 5.66x |
|
NKTR
Nektar Therapeutics
|
66.26% | 7.810 | 16.97% | 4.07x |
|
RCEL
AVITA Medical, Inc.
|
156.64% | -1.611 | 43.77% | 0.44x |
|
RIGL
Rigel Pharmaceuticals, Inc.
|
34.11% | 0.668 | 11.84% | 1.94x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SLNO
Soleno Therapeutics, Inc.
|
$64.9M | $22.7M | -23.2% | -26.56% | 34.41% | $43.6M |
|
ASRT
Assertio Holdings, Inc.
|
$30.2M | $12.9M | -18.41% | -25.86% | 26.09% | -$4.8M |
|
MRKR
Marker Therapeutics, Inc.
|
-- | -$2.1M | -103.04% | -103.04% | -173.31% | -$2.7M |
|
NKTR
Nektar Therapeutics
|
$11.6M | -$31.5M | -54.14% | -327.67% | -267.45% | -$48.9M |
|
RCEL
AVITA Medical, Inc.
|
$14.3M | -$10.4M | -128.41% | -1112.54% | -59.09% | -$4.8M |
|
RIGL
Rigel Pharmaceuticals, Inc.
|
$64.7M | $28.4M | 111.09% | 273.99% | 40.92% | $24M |
Soleno Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns SLNO or ASRT?
Assertio Holdings, Inc. has a net margin of 39.4% compared to Soleno Therapeutics, Inc.'s net margin of 23.14%. Soleno Therapeutics, Inc.'s return on equity of -26.56% beat Assertio Holdings, Inc.'s return on equity of -25.86%.
Company Gross Margin Earnings Per Share Invested Capital SLNOSoleno Therapeutics, Inc.98.27% $0.47 $547.5M ASRTAssertio Holdings, Inc.61.01% $1.61 $150.8M -
What do Analysts Say About SLNO or ASRT?
Soleno Therapeutics, Inc. has a consensus price target of $111.92, signalling upside risk potential of 200.55%. On the other hand Assertio Holdings, Inc. has an analysts' consensus of $39.94 which suggests that it could grow by 222.73%. Given that Assertio Holdings, Inc. has higher upside potential than Soleno Therapeutics, Inc., analysts believe Assertio Holdings, Inc. is more attractive than Soleno Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SLNOSoleno Therapeutics, Inc.11 0 0 ASRTAssertio Holdings, Inc.3 0 0 -
Is SLNO or ASRT More Risky?
Soleno Therapeutics, Inc. has a beta of -3.156, which suggesting that the stock is 415.592% less volatile than S&P 500. In comparison Assertio Holdings, Inc. has a beta of 0.775, suggesting its less volatile than the S&P 500 by 22.468%.
-
Which is a Better Dividend Stock SLNO or ASRT?
Soleno Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Assertio Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics, Inc. pays -- of its earnings as a dividend. Assertio Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLNO or ASRT?
Soleno Therapeutics, Inc. quarterly revenues are $66M, which are larger than Assertio Holdings, Inc. quarterly revenues of $49.5M. Soleno Therapeutics, Inc.'s net income of $26M is higher than Assertio Holdings, Inc.'s net income of $11.4M. Notably, Soleno Therapeutics, Inc.'s price-to-earnings ratio is -- while Assertio Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics, Inc. is 18.45x versus 4.61x for Assertio Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNOSoleno Therapeutics, Inc.18.45x -- $66M $26M ASRTAssertio Holdings, Inc.4.61x -- $49.5M $11.4M
-
Which has Higher Returns SLNO or MRKR?
Marker Therapeutics, Inc. has a net margin of 39.4% compared to Soleno Therapeutics, Inc.'s net margin of -162.11%. Soleno Therapeutics, Inc.'s return on equity of -26.56% beat Marker Therapeutics, Inc.'s return on equity of -103.04%.
Company Gross Margin Earnings Per Share Invested Capital SLNOSoleno Therapeutics, Inc.98.27% $0.47 $547.5M MRKRMarker Therapeutics, Inc.-- -$0.12 $18.4M -
What do Analysts Say About SLNO or MRKR?
Soleno Therapeutics, Inc. has a consensus price target of $111.92, signalling upside risk potential of 200.55%. On the other hand Marker Therapeutics, Inc. has an analysts' consensus of $7.87 which suggests that it could grow by 450.12%. Given that Marker Therapeutics, Inc. has higher upside potential than Soleno Therapeutics, Inc., analysts believe Marker Therapeutics, Inc. is more attractive than Soleno Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SLNOSoleno Therapeutics, Inc.11 0 0 MRKRMarker Therapeutics, Inc.3 0 0 -
Is SLNO or MRKR More Risky?
Soleno Therapeutics, Inc. has a beta of -3.156, which suggesting that the stock is 415.592% less volatile than S&P 500. In comparison Marker Therapeutics, Inc. has a beta of 1.442, suggesting its more volatile than the S&P 500 by 44.218%.
-
Which is a Better Dividend Stock SLNO or MRKR?
Soleno Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Marker Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics, Inc. pays -- of its earnings as a dividend. Marker Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLNO or MRKR?
Soleno Therapeutics, Inc. quarterly revenues are $66M, which are larger than Marker Therapeutics, Inc. quarterly revenues of $1.2M. Soleno Therapeutics, Inc.'s net income of $26M is higher than Marker Therapeutics, Inc.'s net income of -$2M. Notably, Soleno Therapeutics, Inc.'s price-to-earnings ratio is -- while Marker Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics, Inc. is 18.45x versus 3.88x for Marker Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNOSoleno Therapeutics, Inc.18.45x -- $66M $26M MRKRMarker Therapeutics, Inc.3.88x -- $1.2M -$2M
-
Which has Higher Returns SLNO or NKTR?
Nektar Therapeutics has a net margin of 39.4% compared to Soleno Therapeutics, Inc.'s net margin of -301.29%. Soleno Therapeutics, Inc.'s return on equity of -26.56% beat Nektar Therapeutics's return on equity of -327.67%.
Company Gross Margin Earnings Per Share Invested Capital SLNOSoleno Therapeutics, Inc.98.27% $0.47 $547.5M NKTRNektar Therapeutics98.34% -$1.87 $252.2M -
What do Analysts Say About SLNO or NKTR?
Soleno Therapeutics, Inc. has a consensus price target of $111.92, signalling upside risk potential of 200.55%. On the other hand Nektar Therapeutics has an analysts' consensus of $123.43 which suggests that it could grow by 73.04%. Given that Soleno Therapeutics, Inc. has higher upside potential than Nektar Therapeutics, analysts believe Soleno Therapeutics, Inc. is more attractive than Nektar Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings SLNOSoleno Therapeutics, Inc.11 0 0 NKTRNektar Therapeutics7 0 0 -
Is SLNO or NKTR More Risky?
Soleno Therapeutics, Inc. has a beta of -3.156, which suggesting that the stock is 415.592% less volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 1.341, suggesting its more volatile than the S&P 500 by 34.126%.
-
Which is a Better Dividend Stock SLNO or NKTR?
Soleno Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics, Inc. pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLNO or NKTR?
Soleno Therapeutics, Inc. quarterly revenues are $66M, which are larger than Nektar Therapeutics quarterly revenues of $11.8M. Soleno Therapeutics, Inc.'s net income of $26M is higher than Nektar Therapeutics's net income of -$35.5M. Notably, Soleno Therapeutics, Inc.'s price-to-earnings ratio is -- while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics, Inc. is 18.45x versus 73.55x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNOSoleno Therapeutics, Inc.18.45x -- $66M $26M NKTRNektar Therapeutics73.55x -- $11.8M -$35.5M
-
Which has Higher Returns SLNO or RCEL?
AVITA Medical, Inc. has a net margin of 39.4% compared to Soleno Therapeutics, Inc.'s net margin of -65.97%. Soleno Therapeutics, Inc.'s return on equity of -26.56% beat AVITA Medical, Inc.'s return on equity of -1112.54%.
Company Gross Margin Earnings Per Share Invested Capital SLNOSoleno Therapeutics, Inc.98.27% $0.47 $547.5M RCELAVITA Medical, Inc.81.24% -$0.38 $29.4M -
What do Analysts Say About SLNO or RCEL?
Soleno Therapeutics, Inc. has a consensus price target of $111.92, signalling upside risk potential of 200.55%. On the other hand AVITA Medical, Inc. has an analysts' consensus of $8.51 which suggests that it could grow by 76.02%. Given that Soleno Therapeutics, Inc. has higher upside potential than AVITA Medical, Inc., analysts believe Soleno Therapeutics, Inc. is more attractive than AVITA Medical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SLNOSoleno Therapeutics, Inc.11 0 0 RCELAVITA Medical, Inc.3 1 1 -
Is SLNO or RCEL More Risky?
Soleno Therapeutics, Inc. has a beta of -3.156, which suggesting that the stock is 415.592% less volatile than S&P 500. In comparison AVITA Medical, Inc. has a beta of 1.784, suggesting its more volatile than the S&P 500 by 78.388%.
-
Which is a Better Dividend Stock SLNO or RCEL?
Soleno Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AVITA Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics, Inc. pays -- of its earnings as a dividend. AVITA Medical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLNO or RCEL?
Soleno Therapeutics, Inc. quarterly revenues are $66M, which are larger than AVITA Medical, Inc. quarterly revenues of $17.6M. Soleno Therapeutics, Inc.'s net income of $26M is higher than AVITA Medical, Inc.'s net income of -$11.6M. Notably, Soleno Therapeutics, Inc.'s price-to-earnings ratio is -- while AVITA Medical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics, Inc. is 18.45x versus 1.62x for AVITA Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNOSoleno Therapeutics, Inc.18.45x -- $66M $26M RCELAVITA Medical, Inc.1.62x -- $17.6M -$11.6M
-
Which has Higher Returns SLNO or RIGL?
Rigel Pharmaceuticals, Inc. has a net margin of 39.4% compared to Soleno Therapeutics, Inc.'s net margin of 40.17%. Soleno Therapeutics, Inc.'s return on equity of -26.56% beat Rigel Pharmaceuticals, Inc.'s return on equity of 273.99%.
Company Gross Margin Earnings Per Share Invested Capital SLNOSoleno Therapeutics, Inc.98.27% $0.47 $547.5M RIGLRigel Pharmaceuticals, Inc.93.16% $1.46 $178.5M -
What do Analysts Say About SLNO or RIGL?
Soleno Therapeutics, Inc. has a consensus price target of $111.92, signalling upside risk potential of 200.55%. On the other hand Rigel Pharmaceuticals, Inc. has an analysts' consensus of $51.60 which suggests that it could grow by 50.35%. Given that Soleno Therapeutics, Inc. has higher upside potential than Rigel Pharmaceuticals, Inc., analysts believe Soleno Therapeutics, Inc. is more attractive than Rigel Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SLNOSoleno Therapeutics, Inc.11 0 0 RIGLRigel Pharmaceuticals, Inc.3 2 0 -
Is SLNO or RIGL More Risky?
Soleno Therapeutics, Inc. has a beta of -3.156, which suggesting that the stock is 415.592% less volatile than S&P 500. In comparison Rigel Pharmaceuticals, Inc. has a beta of 1.111, suggesting its more volatile than the S&P 500 by 11.137%.
-
Which is a Better Dividend Stock SLNO or RIGL?
Soleno Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rigel Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics, Inc. pays -- of its earnings as a dividend. Rigel Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLNO or RIGL?
Soleno Therapeutics, Inc. quarterly revenues are $66M, which are smaller than Rigel Pharmaceuticals, Inc. quarterly revenues of $69.5M. Soleno Therapeutics, Inc.'s net income of $26M is lower than Rigel Pharmaceuticals, Inc.'s net income of $27.9M. Notably, Soleno Therapeutics, Inc.'s price-to-earnings ratio is -- while Rigel Pharmaceuticals, Inc.'s PE ratio is 5.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics, Inc. is 18.45x versus 2.23x for Rigel Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNOSoleno Therapeutics, Inc.18.45x -- $66M $26M RIGLRigel Pharmaceuticals, Inc.2.23x 5.57x $69.5M $27.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
77
CPS alert for Feb 14
Cooper-Standard Holdings, Inc. [CPS] is up 32.06% over the past day.
Buy
58
TPH alert for Feb 14
Tri Pointe Homes, Inc. [TPH] is up 26.83% over the past day.
Sell
20
IRON alert for Feb 14
Disc Medicine, Inc. [IRON] is down 21.88% over the past day.
